The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m

Srivastava, Suresh C.

doi:10.1590/s1516-89132007000600007

Cited by 16 publications

(10 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the increasing interest in the use of tRT in general and the use of Auger-electron-emitters in particular, more and more centres are now developing novel radiopharmaceuticals labelled with more potent Auger-electron-emitters, with more lowenergy electrons being emitted per decay. Some of the promising radioisotopes include 67 Ga [180], 119 Sb [184], 201 Tl, 165 Ho, 103m Rh [185, 186], 195m Hg [187], and 195m Pt [187]. The main challenge here is the implementation of new chemistries, to make the conjugation of these radionuclides possible.…”

Section: Improving Nuclear Targeted Auger-electron Trtmentioning

confidence: 99%

Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy

Cornelissen¹,

Vallis

2010

CDDT

105

104

View full text Add to dashboard Cite

The review presented here lays out the present state of the art in the field of radionuclide therapies specifically targeted against the nucleus of cancer cells, focussing on the use of Auger-electron-emitters. Nuclear localisation of radionuclides increases DNA damage and cell kill, and, in the case of Auger-electron therapy, is deemed necessary for therapeutic effect. Several strategies will be discussed to direct radionuclides to the nucleoplasm, even to specific protein targets within the nucleus. An overview is given of the applications of Auger-electron-emitting radionuclide therapy targeting the nucleus. Finally, a few suggestions are made as how radioimmunotherapy with nuclear targets can be improved, and the challenges that might be met, such as how to perform accurate dosimetry measurements, are examined.

show abstract

Section: Improving Nuclear Targeted Auger-electron Trtmentioning

confidence: 99%

Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy

Cornelissen¹,

Vallis

2010

CDDT

105

104

View full text Add to dashboard Cite

show abstract

“…Physical and radiation properties of several representative therapeutic bone-targeting radiopharmaceuticals are listed in Table 1 [5][6][7][8][9]. Among them, only 89 Sr-dichloride and 223 Ra-dichloride are clinically available in Korea.…”

Section: Bone-targeting Radiopharmaceuticals For Bone Metastasismentioning

confidence: 99%

Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals

Choi

2018

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and results in serious symptoms and complications such as bone pain, pathological fractures, and spinal cord compression, decreasing quality of life by restricting sleep and mobility. Treatment for bone metastasis includes drugs (pure analgesics, hormones, cytotoxic chemotherapy, and bisphosphonates, among others), external radiation therapy, surgery, and radionuclide therapy using bone-targeting radiopharmaceuticals. Particulate radiation with α- or β-rays is used as a bone-targeting radiopharmaceutical in radionuclide therapy. β-Emitters have lower energy and a longer range than α-emitters and have less tumoricidal activity and deliver more radiation to adjacent normal tissue. Therefore, the main therapeutic effect of bone-targeting β-emitters such as Sr-dichloride is bone pain palliation rather than enhanced survival. In contrast, α-emitters such asRa-dichloride have high energy and a short range, resulting in greater tumoricidal activity and less radiation damage to adjacent normal tissue. Treatment with bone-targeting α-emitters can improve survival and decrease bone pain. This review focuses on the principles and clinical utility of several clinically available bone-targeting radiopharmaceuticals in metastatic bone disease.

show abstract

“…The tumor to non-tumor ratio is not very favorable, and the relief of pain is primarily because of its uptake into mineral bone rather than tumor uptake. In fact, in addition to the skeletal bone uptake, this radiopharmaceutical uptake is also high in rapidly dividing tissues, such as the intestinal wall and the red marrow (Srivastava, 2007).…”

Section: Iiia 32 P-orthophosphatementioning

confidence: 99%

“…The clearance rate from blood appeared to be considerably slower than other bone agents. However, because of its rather long physical halflife relative to these biologic parameters, this is not a concern for radiation absorbed dose in target sites (Srivastava, 2007). The lesion-to-normal bone ratios ranged from as low as 2 to as high as 9…”

Section: Iiid 117m Sn-diethylenetriaminepentaacetic (Dtpa)mentioning

confidence: 99%

Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153

Liberal

Tavares

2016

Applied Radiation and Isotopes

View full text Add to dashboard Cite

Purpose: The present review article aims to provide an overview of the available radionuclides for palliative treatment of bone metastases beyond 89 Sr and 153 Sm. In addition, it aims to review and summarize the clinical outcomes associated with the palliative treatment of bone metastases using different radiopharmaceuticals. Materials and Methods: A literature search was conducted on Science Direct and PubMed databases (1990 -2015). The following search terms were combined in order to obtain relevant results: "bone", "metastases", "palliative", "care", "therapy", "treatment", "radiotherapy", "review", "radiopharmaceutical", "phosphorus-32", "strontium-89", "yttrium-90", "tin-117m", "samarium-153", "holmium-166", "thulium-170", "lutetium-177", "rhenium-186", "rhenium-188" and "radium-223". Studies were included if they provided information regarding the clinical outcomes. Results and Conclusions: A comparative analysis of the measured therapeutic response of different radiopharmaceuticals, based on previously published data, suggests that there is a lack of substantial differences in palliative efficacy among radiopharmaceuticals. However, when the comparative analysis adds factors such as patient's life expectancy, radionuclides' physical characteristics (e.g. tissue penetration range and half-life) and health economics to guide the rational selection of a radiopharmaceutical for palliative treatment of bone metastases, 177 Lu and 188 Re-labeled radiopharmaceuticals appear to be the most suitable radiopharmaceuticals for treatment of small and medium/large size bone lesions, respectively.

show abstract

The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m

Abstract: A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in

Cited by 16 publications

References 27 publications

Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy

Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy

Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals

Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153

Contact Info

Product

Resources

About